RPC has acquired the Peracidin product line from Angelini Pharma, expanding its portfolio of peroxyacetic and peracetic acid sterilants used across dialysis, water treatment and life science applications.
The acquisition broadens RPC’s presence in peracetic acid-based technologies and adds a complementary product line alongside the company’s existing dialysis-focused products.
Peracidin products are used in applications where effective sterilization and disinfection are critical, including dialysis systems, water treatment processes and life science environments.
By adding the Peracidin line, RPC is expanding the range of sterilization technologies it can provide to healthcare, laboratory and other specialized customers.
The transaction also strengthens RPC’s position in a market where reliability, product consistency and technical support are particularly important.
Sterilants used in dialysis and life science environments must meet demanding performance requirements because they are often used in settings where contamination control is essential.
RPC plans to continue supporting existing Peracidin customers following the acquisition.
The company intends to maintain product availability while providing technical support and distribution services as the acquired business is integrated into its broader operating platform.
Maintaining continuity for existing customers will be an important part of the integration process, particularly for healthcare and industrial users that depend on established sterilization products as part of routine operations.
The acquisition gives RPC an opportunity to deepen relationships with customers already using peracetic acid-based products while potentially introducing those customers to additional solutions across the company’s portfolio.
Peracetic acid is widely used as a disinfectant and sterilizing agent because of its effectiveness against a broad range of microorganisms and its applicability across healthcare, water and industrial environments.
For dialysis providers, sterilization and disinfection play an important role in maintaining equipment and supporting safe treatment environments.
RPC has already established a significant presence in the dialysis market, making the Peracidin product line a logical extension of its existing operations.
The company can now offer a broader range of products addressing sterilization requirements within the same customer base.
The acquisition could also create cross-selling opportunities as RPC integrates Peracidin into its existing sales and distribution network.
Customers purchasing dialysis-related products from RPC may have additional requirements for sterilants, cleaning agents or water treatment solutions.
Similarly, Peracidin customers may gain access to RPC’s broader portfolio and technical capabilities.
The transaction therefore expands not only RPC’s product offering but also the potential range of customers and applications the company can serve.
Beyond dialysis, the Peracidin line gives RPC greater exposure to water treatment and life science markets.
Water treatment systems frequently require effective microbial control to maintain water quality and prevent contamination.
Life science organizations similarly rely on sterilization technologies across laboratories, production environments and other controlled settings.
These applications can require dependable products supported by strong manufacturing, quality control and technical expertise.
RPC plans to leverage its existing infrastructure to support the acquired product line while maintaining service for Peracidin customers.
The Tucson, Arizona-based company develops and manufactures products for dialysis providers and related healthcare markets.
RPC also maintains additional operations and production capabilities in Maple Grove, Minnesota.
The company’s U.S. manufacturing and operating footprint provides infrastructure that can support production, distribution and customer service as the Peracidin business is incorporated into the organization.
RPC distributes products to healthcare providers and commercial partners globally, giving the company an established network through which the acquired product line could potentially reach additional markets.
The global distribution capability may create opportunities to expand Peracidin sales beyond its existing customer base over time.
The acquisition also reflects RPC’s broader strategy of building a more comprehensive product platform around dialysis and sterilization technologies.
Adding complementary products can help specialized healthcare suppliers become more important partners to customers by allowing them to address a larger portion of operational requirements through a single vendor.
That can be particularly valuable in dialysis, where providers depend on dependable access to specialized products and supplies.
The transaction gives RPC additional scale within peracetic acid technologies while maintaining its focus on markets where technical expertise and product reliability are significant competitive factors.
RPC can also build on its existing knowledge of dialysis operations when supporting customers using Peracidin products in those environments.
For Angelini Pharma, the transaction transfers ownership of the Peracidin line to a company with a more specialized focus on dialysis and related sterilization applications.
Angelini Pharma is part of Angelini Industries and operates directly in 20 countries.
Its products are commercialized in more than 70 countries, giving the company an extensive international presence across pharmaceutical and healthcare markets.
The Peracidin divestiture allows Angelini Pharma to transfer the product line while RPC assumes responsibility for its continued development, distribution and customer support.
For RPC, the acquisition adds an established line of sterilants that fits closely with its existing technical expertise and customer relationships.
The company can now combine Peracidin with its current dialysis-focused products while expanding further into adjacent applications such as water treatment and life sciences.
The acquisition may also strengthen RPC’s ability to compete for customers seeking suppliers capable of providing both specialized healthcare products and sterilization solutions.
As healthcare providers and life science organizations continue emphasizing infection control, equipment reliability and operational efficiency, demand for effective sterilization products remains important.
RPC is positioning itself to address that demand with a broader portfolio and expanded capabilities following the Peracidin acquisition.
The company plans to prioritize continuity for existing users while gradually integrating the product line into its manufacturing, technical support and distribution operations.
Over time, the acquisition could help RPC deepen its presence in existing markets, reach new customers and expand the range of applications served by its sterilization technologies.
With Peracidin joining its portfolio, RPC is strengthening its position across dialysis, water treatment and life science markets while building on its established manufacturing and distribution capabilities in the U.S. and internationally.
